Factsheet
June 19, 2018

T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level
Q2 Solutions | EA Genomics’ T-cell receptor (TCR) sequencing assay is part of a comprehensive immuno-oncology assay portfolio, available for RUO or GCP applications. The assay is designed to interrogate V(D)J rearrangements in TCRβ and TCRγ chains using RNA or total nucleic acids from whole blood, peripheral blood mononuclear cells (PBMC), or formalin-fixed paraffin-embedded (FFPE) tumor tissue.

It targets and amplifies the TCR complementarity-determining region 3 (CDR3) and incorporates unique molecular indices to facilitate error correction and accurate counting of TCR clonotypes and their abundance and diversity at the mRNA level – using next generation sequencing on Illumina platforms.

Download our factsheet to explore key highlights, specifications, and format by application.

Related Services:
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 11 Immune Landscape Signatures

Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Read More